Patents Examined by Tiffany Nicole Grooms
-
Patent number: 11390886Abstract: The present invention discloses a system for targeted gene editing and related uses.Type: GrantFiled: July 15, 2016Date of Patent: July 19, 2022Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: Shengkan Jin, Juan-Carlos Collantes
-
Patent number: 11365437Abstract: The present invention provides, among other things, methods of quantitating mRNA capping efficiency, particularly for mRNA synthesized in vitro. In some embodiments, the methods comprise chromatographic methods of quantifying capping efficiency and methylation status of the caps.Type: GrantFiled: March 26, 2018Date of Patent: June 21, 2022Assignee: Translate Bio, Inc.Inventors: Michael Heartlein, Frank DeRosa, Anusha Dias
-
Patent number: 11345920Abstract: The invention relates to an artificial nucleic acid molecule comprising an open reading frame and a 3?-UTR comprising at least one poly(A) sequence or a polyadenylation signal. The invention also relates to a method for increasing protein production from an artificial nucleic acid molecule and to the use of a 3?-UTR for a method for increasing protein production from an artificial nucleic acid molecule. Moreover, the invention concerns the use of the artificial nucleic acid molecule as a medicament, as a vaccine or in gene therapy.Type: GrantFiled: December 5, 2021Date of Patent: May 31, 2022Assignee: CureVac AGInventors: Andreas Thess, Thomas Schlake, Stefanie Grund
-
Patent number: 11345933Abstract: Described herein are synthetic oligonucleotides for editing a cell. The oligonucleotides described herein comprise the following covalently-linked components: (i) a nucleic acid encoding a guide RNA (gRNA) sequence targeting a target region in a cell; (ii) a region homologous to the target region comprising a change in sequence relative to the target region; and (iii) a site conferring immunity to nuclease-mediated editing.Type: GrantFiled: December 7, 2021Date of Patent: May 31, 2022Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADOInventors: Andrew Garst, Ryan T Gill
-
Patent number: 11312968Abstract: Strains of yeast genetically engineered to produce increased amounts of non-hydroxylated collagen or hydroxylated collagen are described. An all-in-one vector including the DNA necessary to produce collagen, promotors, and hydroxylating enzymes is also described. Methods for producing non-hydroxylated or hydroxylated collagen are also provided.Type: GrantFiled: June 29, 2018Date of Patent: April 26, 2022Assignee: MODERN MEADOW, INC.Inventors: Lixin Dai, Julia Borden, Jeffrey Nelson, Kristin Ruebling-Jass
-
Patent number: 11293029Abstract: Provided are native promoters comprising polynucleotides isolated from Corynebacterium glutamicum, and mutant promoters derived therefrom, which may be used to regulate, i.e., either increase or decrease, gene expression. Also provided are promoter ladders comprising a plurality of the promoters having incrementally increasing promoter activity. Also provided are host cells and recombinant vectors comprising the promoters, and methods of expressing genes of interest and producing biomolecules using the host cells.Type: GrantFiled: December 7, 2016Date of Patent: April 5, 2022Assignee: Zymergen Inc.Inventors: Zachariah Serber, Katherine G. Gora, Shawn P. Manchester
-
Patent number: 11286468Abstract: Engineered CRISPR-Cas9 nucleases with altered and improved PAM specificities and their use in genomic engineering, epigenomic engineering, and genome targeting.Type: GrantFiled: August 22, 2018Date of Patent: March 29, 2022Assignee: The General Hospital CorporationInventors: J. Keith Joung, Benjamin Kleinstiver
-
Patent number: 11254918Abstract: Compositions and methods are provided for modulating growth of a genetically modified bacterial cell present in a human organ, for modulating growth of a genetically modified bacterial cell in an organ (e.g., gut), for displacing at least a portion of a population of bacterial cells in an organ, and for facilitating gut colonization by a genetically modified bacterial cell. Also provided are genetically modified bacterial cells, e.g., cells that include a heterologous carbohydrate-utilization gene or gene set that provides for the ability to utilize as a carbon source a rare carbohydrate of interest that is utilized as a carbon source by less than 50% of bacterial cells present in a human microbiome.Type: GrantFiled: November 6, 2020Date of Patent: February 22, 2022Assignees: The Board of Trustees of the Leland Stanford Junior University, Novome Biotechnolooies, Inc.Inventors: Justin L. Sonnenburg, Weston R. Whitaker, Elizabeth Stanley, William C. DeLoache
-
Patent number: 11203620Abstract: The present invention provides a modified eukaryotic cell wherein the modified eukaryotic cell is not able to provide an SSN6-like protein that exerts its wildtype function and/or wildtype activity, the amount of SSN6-like protein being present in the modified eukaryotic cell differs from the amount of SSN6-like protein being present in its wildtype form, and/or essentially no SSN6-like protein is present in the modified cell. Additionally, the present invention provides a polynucleotide sequence comprising a modified ssn6-like gene, and a vector comprising said polynucleoptide. Additionally provided is an expression vector comprising a promoter that is repressed in the presence of SSN6-like protein, and a host cell comprising said vectors. The present invention further refers to a method for determining the purity of a composition by using the modified eukaryotic cell, to a method of expressing gene(s) of interest, and eukaryotic cells comprising modified ssn6-like gene.Type: GrantFiled: March 2, 2016Date of Patent: December 21, 2021Assignee: Novartis AGInventors: Clemens Achmüller, Ferdinand Zepeck, Franz Hartner, Thomas Specht
-
Patent number: 11198879Abstract: The present invention provides novel reagents and a cloning procedure based on homologous recombination for the site-directed cloning of a DNA fragment to a vector at designed site(s). The cloning reagents are made of mixture of extracts from at least two different cell types, preferably a mixture made of extracts from wild-type E. coli and S. cerevisiae. Due to the activity of the mixture of cell extracts, recombination occurs between the 3? and 5?-ends of the target DNA and at the ends of linearized vector, which facilitates in-frame construction of expression vectors.Type: GrantFiled: October 25, 2018Date of Patent: December 14, 2021Assignee: VIET NAM NATIONAL UNIVERSITY HO CHI MINH CITYInventors: Phuong Thao Thi Dang, My Trinh Thi Nguyen, Nghia Hieu Nguyen, Thuoc Linh Tran
-
MYO1A for predicting conversion of acute pain into chronic pain and use of MYO1A for therapy of pain
Patent number: 11180791Abstract: Products and methods for assessing the predisposition of a subject to develop an injury-induced chronic mechanical pain and/or an inflammatory-induced chronic thermal pain are provided. More specifically, methods for the assessment of the predisposition of a subject to develop an injury-induced chronic mechanical pain and/or an inflammatory-induced chronic thermal pain using the MYO1A gene as a biomarker and methods of treating selected subjects are provided.Type: GrantFiled: March 7, 2017Date of Patent: November 23, 2021Assignee: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventor: Abdelaziz Moqrich -
Patent number: 11162117Abstract: Provided is a method of activating gene expression using a protein having 90% or more sequence identity to SEQ ID NO:45. The protein activates the expression of a gene upon induction with a medium-chain or long-chain alkane or a medium-chain or long-chain fatty acid methyl ester. Also provided is a whole-cell catalytic system regulated by a medium-chain or long-chain alkane or a medium-chain or long-chain fatty acid methyl ester. The system includes a recombinant microbial cell expressing the protein and an alkane monooxygenase. Also provided is a method of preparing a medium-chain or long-chain alkane terminal oxidation product using the whole-cell catalytic system.Type: GrantFiled: November 15, 2018Date of Patent: November 2, 2021Assignee: NATIONAL TAIWAN UNIVERSITYInventors: Kung-Ta Lee, Shan-Chi Hsieh, Ching-Yeuh Su, Yu-Chen Lai
-
Patent number: 11147830Abstract: The invention relates to methods, uses, systems, arrays, engineered nucleotide sequences and vectors for inhibiting bacterial population growth or for altering the relative ratio of sub-populations of first and second bacteria in a mixed population of bacteria. The invention is particularly useful, for example, for treatment of microbes such as for environmental, medical, food and beverage use The invention relates infer alio to methods of controlling microbiologically influenced corrosion (MIC) or biofouling of a substrate or fluid in an industrial or domestic system.Type: GrantFiled: April 24, 2020Date of Patent: October 19, 2021Assignee: SNIPR Technologies LimitedInventor: Jasper Clube
-
Patent number: 11078498Abstract: Described herein are method for generating a vector for editing a cell. The method comprises ligating into a vector that encodes a portion of a gRNA a cassette comprising at least one editing cassette, a promoter, and a gene encoding another portion of the gRNA. Upon ligation, the portion of the gRNA from the editing cassette and the other portion of the gRNA are ligated and form a functional gRNA.Type: GrantFiled: July 24, 2020Date of Patent: August 3, 2021Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATEInventors: Andrew Garst, Ryan T Gill
-
Patent number: 11066460Abstract: The present invention relates to vectors suitable for use in displaying proteins on the surface of bacteriophage M13 as fusion constructs with the surface protein P.III, bacteriophage M13 particles comprising a mutated P.III protein on the phage coat surface, as well as methods for producing bacteriophage M13 particles and methods for transfecting or infecting a host cell comprising the vectors and bacteriophage of the invention.Type: GrantFiled: November 18, 2016Date of Patent: July 20, 2021Assignee: Eli Lilly and CompanyInventor: Sepideh Afshar
-
Patent number: 11008589Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.Type: GrantFiled: November 23, 2020Date of Patent: May 18, 2021Assignees: The Regents of the University of California, University of ViennaInventors: Jennifer A. Doudna, Martin Jinek, Krzysztof Chylinski, Emmanuelle Charpentier
-
Patent number: 11001858Abstract: The invention provides a bidirectional hCMV-rhCMV promoter and recombinant vectors and recombinant virus comprising the bidirectional hCMV-rhCMV promoter operably linked to a first transgene in one direction and to a second transgene in the opposite direction. The invention also provides methods of making and using such recombinant vectors and recombinant virus.Type: GrantFiled: June 19, 2017Date of Patent: May 11, 2021Assignee: Janssen Vaccines & Prevention B.V.Inventors: Kerstin Wunderlich, Jort Vellinga
-
Patent number: 10988782Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.Type: GrantFiled: October 29, 2020Date of Patent: April 27, 2021Assignees: The Regents of the University of California, University of Vienna, Emmanuelle CharpentierInventors: Jennifer A. Doudna, Martin Jinek, Krzysztof Chylinski, Emmanuelle Charpentier
-
Patent number: 10982230Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together, with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.Type: GrantFiled: July 21, 2020Date of Patent: April 20, 2021Assignees: The Regents of the University of California, University of Vienna, Emmanuelle CharpentierInventors: Jennifer A. Doudna, Martin Jinek, Krzysztof Chylinski, Emmanuelle Charpentier
-
Patent number: 10982231Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.Type: GrantFiled: July 21, 2020Date of Patent: April 20, 2021Assignees: The Regents of the University of California, University of Vienna, Emmanuelle CharpentierInventors: Jennifer A. Doudna, Martin Jinek, Krzysztof Chylinski, Emmanuelle Charpentier